View all ESC 2026 trials
EMAIL-HFDigital HealthOpen Access
Implementation of sodium-glucose co-transporter 2 inhibitors in heart failure through a digital strategy
Key result
Digital outreach increases 6-month SGLT2 inhibitor initiation by ~127% vs usual care.
- P<0.001
Why the trial?
SGLT2 inhibitors improve heart failure outcomes yet remain underprescribed in routine care. EMAIL-HF tested whether a direct-to-patient digital outreach strategy can close this implementation gap and increase initiation of guideline-recommended therapy.
Does a digital outreach strategy improve SGLT2 inhibitor initiation in patients with heart failure?
Population
Patients with heart failure (sample size not reported in the record)
Comparison
Digital outreach strategy for SGLT2 inhibitor initiation vs usual care
Follow-up
6 months
Authors
Discussion
Key questions
No takes yet. Share an insight, caveat, or question.
Where experts stand
Experts view EMAIL-HF as an implementation success that doubled SGLT2 inhibitor starts through digital outreach, though they note it did not translate into clinical outcome benefits in this timeframe.
Clinicians and commentators frame EMAIL-HF as a proof of concept for closing the gap between guideline-recommended therapy and real-world prescribing. The reaction is broadly positive about the digital strategy's ability to boost treatment uptake, but everyone acknowledges the trial showed no outcome signal. The open question is whether longer follow-up or broader adoption would eventually convert higher prescribing into fewer hospitalizations and deaths.
Agreement
Both clinicians who commented substantively agree that the main story is an implementation win: digital outreach can meaningfully close the treatment gap for proven heart failure therapy, even if clinical outcomes did not separate.
2 clinicians say this directly
2 takes classified by contention axis so far — the map appears as more land.
Still unclear
Whether the higher rate of SGLT2 inhibitor initiation will eventually translate into reduced hospitalizations or death with longer follow-up remains unanswered. It is also unclear how scalable the digital strategy is across different health systems and patient populations.
Key expert perspectives
Ahmed BennisHeart Failure / Cardiomyopathy · Centre Hospitalier Universitaire Hassan IIPractice takeAug 29Digital pathways can help close the HF treatment gap
Highlights that the digital strategy more than doubled SGLT2 inhibitor initiation at 6 months (18.6% vs 8.2%) in 5,996 patients with HF. Frames the result as showing digital pathways can move care from evidence to implementation.
Distilled from their postX post
Edgardo Alania · Aug 30 Practice take Calls the result an implementation breakthrough: getting proven therapy to the right patient matters even without early outcome benefit. X post
CF
Chacón-Lozsán F .'. · Aug 30 Context Notes the evidence-practice gap is about implementation, not efficacy, and calls EMAIL-HF a very interesting pragmatic trial. X post
Implication
Digital outreach boosts SGLT2 inhibitor initiation in heart failure; extends implementation evidence for scalable GDMT interventions.
Key Points
- To test the effectiveness of a digital outreach strategy (EMAIL-HF) in initiating guideline-directed SGLT2 inhibitor therapy among patients with heart failure.
- Evaluated the EMAIL-HF digital outreach strategy compared to usual care in patients diagnosed with heart failure.
- Assessed prescription initiation rates of SGLT2 inhibitor therapy and a secondary composite clinical endpoint at 6 months of follow-up.
- SGLT2 inhibitor initiation at 6 months was 18.6% with the digital strategy versus 8.2% with usual care (p<0.001).
- The secondary composite endpoint of heart-failure hospitalisation or death occurred in 13.0% in the digital strategy arm versus 14.0% with usual care (p=0.276).
Evidence details
What drove the result?
| Outcome | Digital | Usual care |
|---|---|---|
| SGLT2 inhibitor initiation at 6 months | 18.6% | 8.2% |
| p<0.001 favouring digital outreach | ||
| HF hospitalisation or death | 13.0% | 14.0% |
| Secondary outcome · p=0.276, not significant | ||
Limitations & tradeoffs
Statistical certainty
sample size, denominators and design details are not reported.
Design limitations
record is derived from the ESC press release with no simultaneous results paper, and clinical-outcome follow-up is limited to 6 months, too short to expect an initiation gain to translate into events.
Structured PICO
Does a digital outreach strategy improve SGLT2 inhibitor initiation in patients with heart failure?
P
Population
Patients with heart failure followed for 6 months.
I
Intervention
digital outreach strategy to start proven SGLT2 inhibitor therapy
C
Comparator
usual care
O
Outcome
SGLT2 inhibitor initiation at 6 months
Main Result
Absolute Event Rate: 18.6% vs 8.2%
p-value: p=<0.001
A digital outreach strategy significantly increased the initiation of guideline-directed SGLT2 inhibitors in patients with heart failure compared to usual care.
Coverage & sources
Journal, society, and media accounts. Useful signal, not independent expert judgment.
Cite This Study
Mariam Elmegaard (2026) conducted an RCT in heart failure. digital outreach strategy vs. usual care was evaluated on SGLT2 inhibitor initiation (p=<0.001). A digital outreach strategy significantly increased SGLT2 inhibitor initiation at 6 months compared to usual care (18.6% vs 8.2%, p<0.001).